Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference [Yahoo! Finance]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Yahoo! Finance
Phase 2 trial for moderate-to-severe atopic dermatitis read out in the back half of the year and ATI-052 (bispecific) showing early PD signals including a claimed "100% inhibition" and additional SAD/MAD readouts due in early Q2 ahead of a planned Phase 2b in asthma. On the small-molecule side, ATI-2138 is Phase-2 ready with indication selection imminent, and the next-gen ITK candidate ATI-9494 has an IND planned in H2 , with company data suggesting substantially improved potency and a design that removes a JAK component to potentially improve safety and dosing. Management says its cash runway extends into Q4 2028 , which it believes funds the discussed milestones and provides flexibility to expand development across its biologics and small-molecule programs. Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. 3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices Aclaris Therapeutics (NASDAQ:ACRS) outlined multiple clinical and near-term d
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswire
- Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052GlobeNewswire
ACRS
Earnings
- 2/26/26 - Miss
ACRS
Sec Filings
- 3/11/26 - Form 8-K
- 3/10/26 - Form 8-K
- 3/3/26 - Form 4
- ACRS's page on the SEC website